Thalidomide promotes transplanted cell engraftment in the rat liver by modulating inflammation and endothelial integrity

Preeti Viswanathan, Priya Gupta, Sorabh Kapoor, Sanjeev Gupta

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background & Aims: For liver-directed cell therapy, efficient engraftment of transplanted cells is critical. This study delineated whether anti-inflammatory and endothelial disrupting properties of thalidomide could promote transplanted cell engraftment and proliferation in liver. Methods: We used dipeptidyl peptidase IV-deficient rats for cell transplantation studies, including gene expression analysis, morphological tissue analysis, serological assays, cell culture assays, and assays of transplanted cell engraftment and proliferation. Results: Thalidomide-pretreatment increased engraftment and proliferation of transplanted hepatocytes due to decreased inflammation. Moreover, thalidomide exacerbated cell transplantation-induced endothelial injury. This combined anti-inflammatory and endothelial injury effect of thalidomide was superior to the anti-inflammatory effect alone of repertaxin or etanercept, which block cytokines/chemokines/receptor-dependent inflammation. In thalidomide-pretreated animals, liver repopulation accelerated, including when cells were primed with bosentan to block endothelin-1 receptors. Conclusions: Thalidomide improved transplanted cell engraftment and liver repopulation. Therefore, this class of drugs will advance applications of liver cell therapy in people. Lay summary: This work aimed to develop effective drug treatments for improving engraftment of transplanted cells because that constitutes a critical step in rebuilding liver with healthy cells. Studies in animal models of cell transplantation led to identification of an old drug, thalidomide, which blocked inflammation and altered the liver microenvironment to yield superior engraftment and proliferation of transplanted cells. This will be appropriate for liver cell therapy in people.

Original languageEnglish (US)
JournalJournal of Hepatology
DOIs
StateAccepted/In press - Oct 30 2015

Fingerprint

Thalidomide
Inflammation
Liver
Cell Transplantation
Cell- and Tissue-Based Therapy
Anti-Inflammatory Agents
Cell Proliferation
Pharmaceutical Preparations
Dipeptidyl Peptidase 4
Endothelin A Receptors
Cytokine Receptors
Chemokine Receptors
Wounds and Injuries
Hepatocytes
Animal Models
Cell Culture Techniques
Gene Expression

Keywords

  • Cell therapy
  • Endothelium
  • Inflammation
  • Transplantation

ASJC Scopus subject areas

  • Hepatology

Cite this

@article{8049d9fad1504f66acb986da63b8ced3,
title = "Thalidomide promotes transplanted cell engraftment in the rat liver by modulating inflammation and endothelial integrity",
abstract = "Background & Aims: For liver-directed cell therapy, efficient engraftment of transplanted cells is critical. This study delineated whether anti-inflammatory and endothelial disrupting properties of thalidomide could promote transplanted cell engraftment and proliferation in liver. Methods: We used dipeptidyl peptidase IV-deficient rats for cell transplantation studies, including gene expression analysis, morphological tissue analysis, serological assays, cell culture assays, and assays of transplanted cell engraftment and proliferation. Results: Thalidomide-pretreatment increased engraftment and proliferation of transplanted hepatocytes due to decreased inflammation. Moreover, thalidomide exacerbated cell transplantation-induced endothelial injury. This combined anti-inflammatory and endothelial injury effect of thalidomide was superior to the anti-inflammatory effect alone of repertaxin or etanercept, which block cytokines/chemokines/receptor-dependent inflammation. In thalidomide-pretreated animals, liver repopulation accelerated, including when cells were primed with bosentan to block endothelin-1 receptors. Conclusions: Thalidomide improved transplanted cell engraftment and liver repopulation. Therefore, this class of drugs will advance applications of liver cell therapy in people. Lay summary: This work aimed to develop effective drug treatments for improving engraftment of transplanted cells because that constitutes a critical step in rebuilding liver with healthy cells. Studies in animal models of cell transplantation led to identification of an old drug, thalidomide, which blocked inflammation and altered the liver microenvironment to yield superior engraftment and proliferation of transplanted cells. This will be appropriate for liver cell therapy in people.",
keywords = "Cell therapy, Endothelium, Inflammation, Transplantation",
author = "Preeti Viswanathan and Priya Gupta and Sorabh Kapoor and Sanjeev Gupta",
year = "2015",
month = "10",
day = "30",
doi = "10.1016/j.jhep.2016.07.008",
language = "English (US)",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",

}

TY - JOUR

T1 - Thalidomide promotes transplanted cell engraftment in the rat liver by modulating inflammation and endothelial integrity

AU - Viswanathan, Preeti

AU - Gupta, Priya

AU - Kapoor, Sorabh

AU - Gupta, Sanjeev

PY - 2015/10/30

Y1 - 2015/10/30

N2 - Background & Aims: For liver-directed cell therapy, efficient engraftment of transplanted cells is critical. This study delineated whether anti-inflammatory and endothelial disrupting properties of thalidomide could promote transplanted cell engraftment and proliferation in liver. Methods: We used dipeptidyl peptidase IV-deficient rats for cell transplantation studies, including gene expression analysis, morphological tissue analysis, serological assays, cell culture assays, and assays of transplanted cell engraftment and proliferation. Results: Thalidomide-pretreatment increased engraftment and proliferation of transplanted hepatocytes due to decreased inflammation. Moreover, thalidomide exacerbated cell transplantation-induced endothelial injury. This combined anti-inflammatory and endothelial injury effect of thalidomide was superior to the anti-inflammatory effect alone of repertaxin or etanercept, which block cytokines/chemokines/receptor-dependent inflammation. In thalidomide-pretreated animals, liver repopulation accelerated, including when cells were primed with bosentan to block endothelin-1 receptors. Conclusions: Thalidomide improved transplanted cell engraftment and liver repopulation. Therefore, this class of drugs will advance applications of liver cell therapy in people. Lay summary: This work aimed to develop effective drug treatments for improving engraftment of transplanted cells because that constitutes a critical step in rebuilding liver with healthy cells. Studies in animal models of cell transplantation led to identification of an old drug, thalidomide, which blocked inflammation and altered the liver microenvironment to yield superior engraftment and proliferation of transplanted cells. This will be appropriate for liver cell therapy in people.

AB - Background & Aims: For liver-directed cell therapy, efficient engraftment of transplanted cells is critical. This study delineated whether anti-inflammatory and endothelial disrupting properties of thalidomide could promote transplanted cell engraftment and proliferation in liver. Methods: We used dipeptidyl peptidase IV-deficient rats for cell transplantation studies, including gene expression analysis, morphological tissue analysis, serological assays, cell culture assays, and assays of transplanted cell engraftment and proliferation. Results: Thalidomide-pretreatment increased engraftment and proliferation of transplanted hepatocytes due to decreased inflammation. Moreover, thalidomide exacerbated cell transplantation-induced endothelial injury. This combined anti-inflammatory and endothelial injury effect of thalidomide was superior to the anti-inflammatory effect alone of repertaxin or etanercept, which block cytokines/chemokines/receptor-dependent inflammation. In thalidomide-pretreated animals, liver repopulation accelerated, including when cells were primed with bosentan to block endothelin-1 receptors. Conclusions: Thalidomide improved transplanted cell engraftment and liver repopulation. Therefore, this class of drugs will advance applications of liver cell therapy in people. Lay summary: This work aimed to develop effective drug treatments for improving engraftment of transplanted cells because that constitutes a critical step in rebuilding liver with healthy cells. Studies in animal models of cell transplantation led to identification of an old drug, thalidomide, which blocked inflammation and altered the liver microenvironment to yield superior engraftment and proliferation of transplanted cells. This will be appropriate for liver cell therapy in people.

KW - Cell therapy

KW - Endothelium

KW - Inflammation

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84994508588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994508588&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2016.07.008

DO - 10.1016/j.jhep.2016.07.008

M3 - Article

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

ER -